Exact Sciences

Earlier cancer detection changes lives. In just 10 years, the Cologuard® test has been used more than 16 million times, helping average risk patients and their families make more time for the moments that matter. Learn more: https://bit.ly/473HaiA #10YearsofCologuard

Innovation is one of our core values at Exact Sciences. New ideas enable us to work toward our purpose of helping eradicate cancer. Find out how fresh thinking from students at the Savannah College of Art and Design, Arizona State University, and University of Wisconsin-Madison revealed even more ways to help support our patients: https://bit.ly/3T1Obut

From a groundbreaking idea to an FDA-approved screening tool for average risk patients, the growth of the Cologuard® test was no small feat. Hear some of the unforgettable moments from the Cologuard test’s first 10 years, as told by the team that helped make it happen: https://lnkd.in/gTB2xsR5 #10YearsofCologuard 

In the final episode of our #10YearsofCologuard series, ten years have passed since Exact Sciences processed its first Cologuard® test. Patients, physicians, and the Exact Sciences team reflect on the test’s impact and look ahead to the next chapter in Cologuard history.  Watch the full series here: https://bit.ly/3AyCUvj

In episode 4 of our #10YearsofCologuard series, Exact Sciences and the Cologuard® brand have a pop culture moment. A high-profile annual event brings together advocates for screening and builds community among those touched by colorectal cancer. The company works to reach people who remain unscreened.

In episode 3 of our #10YearsofCologuard series, the Exact Sciences team pulls together to address a staggering setback and figures out how to move forward. The company introduces a surprising method for promoting the Cologuard® test to customers. As demand for the test skyrockets, the company steps up to respond. 

In episode 2 of our #10YearsofCologuard series, Exact Sciences decides to go big to prove out its new colorectal cancer screening test. It launches an ambitious clinical study led by a noted physician and accepts an invitation to try a never-been-done approach for seeking approval from regulators. An unexpected development threatens to derail everything. 

We’ve enrolled the first patient in the Falcon Registry study! This real-world evidence (RWE) study will use the Exact Sciences MCED test, which recently received an investigational device exemption from the FDA, to assess the clinical impact of multi-cancer early detection testing. Through our primary study sites, Baylor Scott & White Health and Endeavor Health, this trial will help pave the way for our future MCED test in development and help expand the range of cancers that may be detected through screening. Read more and follow our journey as we work to redefine the possibilities of early cancer detection: https://bit.ly/3XaaWPf

Play ball! ⚾ Lil’ CG (aka Pete Perales) made his major league debut on Saturday as he threw the ceremonial first pitch at the Chicago Cubs game in support of the ‘Cubs for a Cure’ initiative. It was an honor to spend a weekend at the ballpark to help raise awareness for cancer research and prevention! Video courtesy of the Cubs

In episode 1 of our #10YearsofCologuard series, the screening challenge needs a bold vision and the right research to come together. A new group of leaders joins Exact Sciences. Through key collaborations, the company develops a product it believes will greatly impact the number of people getting screened for colorectal cancer — and how they screen.